Specialised singing programmes can improve symptoms and QoL of people with lung disease: Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Severe Emphysema on HRCT Signals Higher Heart Disease Risk in COPD Patients: Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
CAT-Based Definition Better Predicts COPD Mortality Risk, reports research We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Lupin Secures CDSCO Panel Clearance for Phase III COPD Inhaler Trial We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Rising Burden of Asthma and COPD Among Older Indians Linked to Social and Household Factors, Finds Study We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
AstraZeneca’s hopes of a big new indication for respiratory drug Fasenra in chronic obstructive pulmonary disease (COPD) have been dashed by a negative phase 3 trial. The RESOLUTE study of IL-5 inhibitor Fasenra (benralizumab) showed some improvement with Fasenra compared to placebo in reducing COPD exacerbations, or attacks, that signal progression of the debilitating and…
AstraZeneca said on Wednesday its asthma drug Fasenra failed to control the rate of flare-ups in patients with chronic obstructive pulmonary disease (COPD) in a late-stage study, in a setback to efforts to help tackle a severe lung disease. The drugmaker said Fasenra did not meet the primary endpoint in COPD patients compared with placebo,…
Betel Quid Use Linked to Higher Risk of COPD Deaths, Study Finds We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
15 Percent of COPD Exacerbation Patients Develop Arrhythmias, Tripling In-Hospital Death Risk: Meta-Analysis We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Dad’s childhood passive smoking may confer lifelong poor lung health onto his kids We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link